Dermapharm Holding Past Earnings Performance
Past criteria checks 2/6
Dermapharm Holding has been growing earnings at an average annual rate of 8.4%, while the Pharmaceuticals industry saw earnings declining at 0.9% annually. Revenues have been growing at an average rate of 12.9% per year. Dermapharm Holding's return on equity is 9.3%, and it has net margins of 5%.
Key information
8.4%
Earnings growth rate
8.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 12.9% |
| Return on equity | 9.3% |
| Net Margin | 5.0% |
| Next Earnings Update | 14 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Dermapharm Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,129 | 57 | 274 | 0 |
| 31 Dec 23 | 1,151 | 62 | 271 | 0 |
| 30 Sep 23 | 1,172 | 95 | 248 | 0 |
| 30 Jun 23 | 1,151 | 123 | 227 | 0 |
| 31 Mar 23 | 1,128 | 146 | 212 | 0 |
| 31 Dec 22 | 1,041 | 134 | 191 | 0 |
| 30 Sep 22 | 1,024 | 176 | 185 | 0 |
| 30 Jun 22 | 1,004 | 185 | 180 | 0 |
| 31 Mar 22 | 980 | 211 | 173 | 0 |
| 31 Dec 21 | 960 | 210 | 169 | 0 |
| 30 Sep 21 | 902 | 162 | 168 | 0 |
| 30 Jun 21 | 858 | 123 | 167 | 0 |
| 31 Mar 21 | 828 | 95 | 168 | 0 |
| 31 Dec 20 | 808 | 86 | 158 | 0 |
| 30 Sep 20 | 775 | 80 | 142 | 0 |
| 30 Jun 20 | 760 | 77 | 134 | 0 |
| 31 Mar 20 | 743 | 85 | 119 | 0 |
| 31 Dec 19 | 714 | 77 | 116 | 0 |
| 30 Sep 19 | 674 | 73 | 114 | 0 |
| 30 Jun 19 | 639 | 77 | 105 | 0 |
| 31 Mar 19 | 611 | 73 | 100 | 0 |
| 31 Dec 18 | 584 | 75 | 92 | 0 |
| 30 Sep 18 | 558 | 75 | 96 | 0 |
| 30 Jun 18 | 525 | 76 | 89 | 0 |
| 31 Mar 18 | 498 | 79 | 82 | 0 |
| 31 Dec 17 | 480 | 78 | 78 | 0 |
| 30 Sep 17 | 486 | 84 | 70 | 0 |
| 31 Dec 16 | 455 | 77 | 71 | 0 |
| 31 Dec 15 | 396 | 13 | 65 | 0 |
| 31 Dec 14 | 402 | 0 | 67 | 0 |
Quality Earnings: 0A5J has high quality earnings.
Growing Profit Margin: 0A5J's current net profit margins (5%) are lower than last year (13%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0A5J's earnings have grown by 8.4% per year over the past 5 years.
Accelerating Growth: 0A5J's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 0A5J had negative earnings growth (-61.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (1.3%).
Return on Equity
High ROE: 0A5J's Return on Equity (9.3%) is considered low.